KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Other Non Operating Income (2016 - 2025)

Historic Other Non Operating Income for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $102000.0.

  • Jazz Pharmaceuticals' Other Non Operating Income rose 11455.06% to $102000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.7 million, marking a year-over-year decrease of 21643.45%. This contributed to the annual value of -$8.2 million for FY2024, which is 19311.48% down from last year.
  • Latest data reveals that Jazz Pharmaceuticals reported Other Non Operating Income of $102000.0 as of Q3 2025, which was up 11455.06% from -$1.8 million recorded in Q2 2025.
  • In the past 5 years, Jazz Pharmaceuticals' Other Non Operating Income ranged from a high of $9.4 million in Q4 2023 and a low of -$10.5 million during Q1 2022
  • For the 5-year period, Jazz Pharmaceuticals' Other Non Operating Income averaged around -$1.4 million, with its median value being -$1.5 million (2023).
  • Its Other Non Operating Income has fluctuated over the past 5 years, first soared by 73577.59% in 2021, then plummeted by 121770.94% in 2022.
  • Over the past 5 years, Jazz Pharmaceuticals' Other Non Operating Income (Quarter) stood at -$5.6 million in 2021, then skyrocketed by 55.77% to -$2.5 million in 2022, then soared by 476.83% to $9.4 million in 2023, then tumbled by 167.3% to -$6.3 million in 2024, then soared by 101.62% to $102000.0 in 2025.
  • Its Other Non Operating Income stands at $102000.0 for Q3 2025, versus -$1.8 million for Q2 2025 and -$6.3 million for Q4 2024.